CTLA4 and neoplasm: Patients over 54 years of age with non-superficial tumor, Clark level III–IV, stage III or IV, and with CTLA-4 c.-1577 AA genotype had a 1.80-, 4.87-, 4.37-, 3.43-, and 1.60-times greater chance of recurrence, disease progression, or death related to tumor effects, respectively.